Navigation Links
Survival rates in breast cancer patients improved with "Dose Dense Chemotherapy"

A study conducted by the Cancer and Leukemia Group B (CALGB) and presented at the 25th Annual San Antonio Breast Cancer Symposium assessed the effectiveness of reducing the interval between successive doses of a commonly used chemotherapy regimen to improve survival rates in breast cancer// women. This study was conducted as follow-up of a mathematical model which was developed in the 1980s that suggested the value of increased dose density.

Researchers tested both dose dense and conventional chemotherapy regimens in 1,973 women with node-positive primary breast cancer and no other metastases. Following surgical removal of their tumors, the women were assigned to one of four treatment regimens involving the standard chemotherapy drugs doxorubicin (A), paclitaxel (T), and cyclophosphamide (C):

Sequential administration (A followed by T, followed by C) in three-week intervals (conventional)

Sequential administration in two-week intervals, with filgrastim (dose dense)

Concurrent administration (A and C together, followed by T) in three-week intervals

Concurrent administration in two-week intervals, with filgrastim (dose dense)

The dose dense regimen was made tolerable to patients with the drug filgrastim, which helps prevent neutropenia, a serious complication of chemotherapy. In neutropenia there is a decline in the number of a certain type of white blood cells which hampers the immune system of the body. Filgrastim, also known as the granulocyte-colony stimulating factor (G-CSF), helps prevent neutropenia by stimulating the formation of white blood cells called neutrophils. Without it, chemotherapy dosing frequency is limited to longer intervals.

The researchers found that the disease-free survival was 82 per cent after four years compared to 75 percent for those who received conventional therapy. This difference corresponded to a 26 percent overall reduction in the risk of cancer recurre nce. They also found that the efficacy did not differ between the two dose regimens.

The study also indicated that dose dense chemotherapy could lead to higher overall survival rates. After three years, 92 percent of patients on the dose dense therapy were alive, compared to 90 percent of those on the conventionally administered regimens. This difference corresponded to a 31 percent overall reduction in the risk of death. However, the study authors cautioned that additional follow-up is necessary to confirm this overall survival benefit.

The study also found that patients on dose dense chemotherapy did not have increased side effects than those on the conventional treatments. It was also found that sequential administration produced slightly fewer side effects than the concurrent regimens, with equal efficacy.

Larry Norton, M.D., of Memorial Sloan-Kettering Cancer Center, Senior investigator of the study believed that this study which showed an improvement due to dose dense chemotherapy could advance knowledge of the biology of breast cancer and how best to treat it. He also added that further confirmed studies would affect the care of thousands of patients throughout the world with breast cancer and perhaps, eventually, other diseases.

Researchers also hypothesize that future clinical trials could examine the benefits of dose dense chemotherapy using other drugs and in other types of cancer as the mathematical model on which the study was based applied to most cancer types and many anti-cancer drugs.


'"/>




Related medicine news :

1. Long-Term Survival can be Predicted by a Simple Lung Test
2. Hepatitis G May Boost HIV Survival
3. Longer Lung Cancer Survival
4. ICU Survival can be improved by Antibiotic use
5. Vasopressin Found To Boost Survival In Sudden Cardiac arrest
6. Improving Survival Rate Of Lung Cancer Patients
7. Combination Therapy Effective In Improving Lung Cancer Survival
8. Symptoms Found To Be A Good Predictor Of Cancer Survival
9. Survival Of Colon Cancer Patients
10. Public Defibrillators Found To Improve Survival Rate
11. Body Weight Found To Affect Breast Cancer Survival
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/21/2017)... ... 21, 2017 , ... "ProDOF is the perfect set of tools for video editors that want ... scene," said Christina Austin - CEO of Pixel Film Studios. , Video editors using ... illusion of a DSLR racking focus from one area into the next. ProDOF comes ...
(Date:1/21/2017)... ... January 21, 2017 , ... ... Relations, Dianne Travis-Teague, the electrifying line-up of events for its annual meeting “Coming ... friends, and community. “Coming Home 2017” will be held on Friday January ...
(Date:1/21/2017)... ... January 21, 2017 , ... In the United States, ... experience the freedom of recovery, they often feel shame for having struggled with an ... disorder (PTSD). In the workshop, “Rising Strong in Life After an Eating Disorder” -- ...
(Date:1/20/2017)... , ... January 20, 2017 , ... A new partnership ... items they no longer use or need, from clothes to couches to dressers and ... items and take them to the nearest Goodwill donation center through February 28th. ...
(Date:1/20/2017)... FL (PRWEB) , ... January 20, 2017 , ... Doctor ... announced it attended the January ECRM trade show to continue the marketing and distribution ... vitamin C supplement, known for providing 400 percent better absorption than traditional vitamin C ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... NEW YORK , Jan. 19, 2017 /PRNewswire/ ... reach USD 233.7 billion by 2025, according to ... The market is anticipated to be predominantly driven ... companies, resulting into the large-scale production of new ... widen the influx of drugs at an unprecedented ...
(Date:1/19/2017)... Conference Call and Webcast to Follow Vanda Pharmaceuticals Inc. ... results for the fourth quarter of 2016 on Wednesday, February 15, ... ... PM ET on Wednesday, February 15, 2017, during which management will ... other corporate activities. To participate in the conference call, please dial ...
(Date:1/19/2017)... 19, 2017  Stealth BioTherapeutics Inc. ( Stealth ), ... dysfunction, today announced new additions to its senior leadership ... Medical Officer, and Daniel Geffken as interim ... Jim Carr , Pharm.D. has been promoted to Chief ... to welcome Doug and Daniel to our management team, ...
Breaking Medicine Technology: